From these observations, it is suggested that the suppressive effect of bortezomib on DSS-colitis is closely associated with inhibition of proteasome degradation of ubiquitinated IκBα in the colonic epithelial cells and this leads to a suppression of NF-κB activation. Here, NFKB1 is linked to colitis.